Acute pneumonitis secondary to subcutaneous silicone injection

Priya Gopie
Sateesh Sakhamuri
Anu Sharma
Sanjeev Solomon
Surujpal Teelucksingh
Clinical Medical Sciences,
University of the West Indies,
St Augustine, Trinidad

Abstract: Following silicone injection, end organ toxicity can occur. To our knowledge this report documents the first case of silicone embolization in the Caribbean and serves to highlight an emergent danger associated with its illicit use for cosmetic purposes in this region.

Keywords: silicone, silicone embolism, silicone pneumonitis, alveolar hemorrhage, pneumonitis

Case

A 38-year-old female presented to the emergency department with sudden onset of shortness of breath, chest pain, and hemoptysis. On examination, the patient was afebrile and positive findings included tachycardia (pulse rate of 130 beats per minute), tachypnea (respiratory rate of 35 breaths per minute), and SpO$_2$ by pulse oximetry was 86% on room air. The trachea was central and there was symmetrical chest expansion, with resonance on percussion and clear breath sounds bilaterally. Arterial blood gas results revealed hypoxemia and a respiratory alkalosis (pH: 7.46; pCO$_2$: 30 mmHg; pO$_2$: 55 mmHg; HCO$_3$: 22 mmol/L; SaO$_2$: 88%). Initial chest X-ray was normal and CT pulmonary angiography (CTPA) showed no evidence of pulmonary embolism, but there was basal and peripheral interstitial shadowing bilaterally (Figure 1). The clinical impression at that time was acute interstitial pneumonia with possible pulmonary embolism (PE). High flow O$_2$ was administered together with intravenous levofoxacin 750 mg orally and intravenous hydrocortisone 200 mg every 6 hours. Since the patient's coagulation profile was normal and there were no obvious vascular deformities noted in CT scan, subcutaneous enoxaparin 60 mg twice daily was also started. By day 3, her condition had worsened with increasing hemoptysis and decreasing SpO$_2$ ranging from 83% to 85%. Repeat arterial blood gas was consistent with worsening hypoxemia and partially compensated respiratory alkalosis (pH: 7.48; pCO$_2$: 26 mmHg; pO$_2$: 50 mmHg; HCO$_3$: 18 mmol/L; SaO$_2$: 80%). Chest examination now revealed crepitations bilaterally in both bases, and chest X-ray showed bilateral basal nonhomogeneous opacities with obliteration of costophrenic angles (Figure 2). The patient was repeatedly counseled about the seriousness of her condition and further inquiry revealed that the patient had received silicone injection on her buttocks, 6 hours prior to her presentation. Approximately 500 mL of silicone was administered by an unlicensed aesthetician. Over the next few days, the patient's...
oxygenation improved but she had persistent hemoptysis, resulting in a drop in hemoglobin from 11 g/dL to 9 g/dL requiring transfusion with two units of packed red blood cells. It was also noted that there was whitish material admixed on the sputum. (Figure 3) This was sent for sputum cytology which revealed inflammatory cells containing neutrophils and lymphocytes. Of note, her repeat chemistry at this time showed an elevated aspartate aminotransferase (AST) of 110. By day 7, the patient was showing clinical signs of improvement with SpO₂ ranging from 93% to 95%. By day 13, the patient had no hemoptysis and her SpO₂ was 98% on room air. Spirometry on day 14 revealed moderate restrictive defect (Table 1) and she was discharged from hospital. At follow-up clinic, the patient was symptom-free. She was continued on oral steroids for 4 weeks and anticoagulated with warfarin for 6 months. Radiological resolution and spirometry normalization (Table 1) occurred after 4 weeks, whereas, elevated AST were normalized only after 8 weeks.

**Discussion**

Liquid silicone is a polymer (dimethylpolysiloxane) that has been widely used for aesthetic purposes since the 1960s.¹ Despite the dangers and long history of fatalities, disease, and disfigurement caused by silicone injection, its illicit use is still common around the world.

Two distinct patterns of clinical presentation are seen after injection of silicone enters the systemic circulation: either respiratory distress, which occurred in this present report, or severe neurological changes.² The first case of

**Table 1** Spirometry on day 14 (after hemoptysis control) and at follow-up clinic (after 1 month)

|                          | Day 14          | 1 month        |
|--------------------------|-----------------|----------------|
| FEV₁/FVC%                | 90.8 (61% of predicted) | 86.5 (62% of predicted) |
| FEV₁                    | 1.38 L          | 1.86 L (82% of predicted) |
| FVC                     | 1.52 L (58% of predicted) | 2.15 (75% of predicted) |
| FEF₂₅₋₇₅%               | 2.29 L (62% of predicted) | 2.74 (75% of predicted) |

**Abbreviations:** FEV₁, forced expiratory volume in the first second of expiration; FVC, forced vital capacity; FEF, forced expiratory flow, midexpiratory phase.

---

Figure 1 CT pulmonary angiography showing basal and peripheral interstitial shadowing bilaterally.

Figure 2 Chest X-ray showing bilateral patchy opacification.

Figure 3 Hemoptysis contents with whitish material admixed on the sputum.
pneumonitis following silicone injection was described in 1975. The acute form of pneumonitis following silicone injection, as seen in this patient, appears immediately or within 24 hours after injection, with sudden-onset dyspnea, tachycardia, tachypnea, fever, and, occasionally, chest pain or hemoptysis. The pathogenesis of acute pneumonitis involves a process of pulmonary embolism following the diffusion of the silicone into the circulatory system, encouraged by high local tissue pressure, massages, migration, or direct injection.

The index case presented with severe respiratory distress a few hours after silicone injection. With incomplete history from the patient, PE with acute interstitial lung inflammation was suspected. Now, a negative multidetector CT (CTPA) is an adequate criterion for excluding PE in patients with a nonhigh clinical probability of PE. However, this case belonged to a high probability class and subsegmental emboli were feasible. Whether patients with a negative CT and a high clinical probability should be further investigated by other methods is controversial. Moreover currently there are no straightforward accepted guidelines for treatment of subsegmental PE.

Additionally silicone embolization to the lung is associated with alveolar hemorrhage. In the present case, hemoptysis might be secondary to alveolar hemorrhage and/or pulmonary infarction, which was managed with two units of packed red blood cells transfusion. Normal connective tissue and coagulation profiles, renal functions, and anatomically normal vasculature in CT scan precluded the possibility of other causes for pulmonary hemorrhage. Despite its high value, bronchoscopy was deferred due to potential worsening hypoxemia. It is a well-known fact that arterial oxygen tension routinely decreases by 10 to 20 mmHg after uncomplicated fiberoptic bronchoscopy, and hypoxicemic patients are at high risk for developing respiratory failure or serious cardiac arrhythmias.

Systemic complications have also been reported after silicone use and include mastitis, granulomatous hepatitis, connective tissue disease, lymphadenopathy, and acute febrile reaction. This patient’s persistently elevated AST may have occurred on account of silicone migration to the liver, but conservative treatment was undertaken and resolution was complete.

This case highlights a serious complication of an apparently innocuous process, of which clinicians and the public should be made aware. Clandestine injection of silicone for body enhancement is common and clinicians should be aware of potential complications. A history of cosmetic procedures involving silicone should be considered in unusual cases of the nature presented here.

Disclosure
The authors declare no conflicts of interest in this work.

References
1. Ellenbogen R, Ellenbogen R, Rubin L. Injectable fluid silicone therapy: human morbidity and mortality. JAMA. 1975;234:308–309.
2. Schmid A, Tzur A, Lesko L, Krieger BP. Silicone embolism syndrome: a case report, review of the literature, and comparison with fat embolism syndrome. Chest. 2005;127:2276–2281.
3. Pastor E, Andreu AL, Chiner E. Acute pneumonitis and adult respiratory distress syndrome after subcutaneous injection of liquid silicone. Arch Bronconeumol. 2005;41:702–703.
4. Guidelines on the diagnosis and management of acute pulmonary embolism, The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J. 2008;29:2276–2315.
5. Parikh R, Karim K, Parikh N, Han P, Daoko J, Shamoon FE. Case report and literature review: acute pneumonitis and alveolar hemorrhage after subcutaneous injection of liquid silicone. Ann Clin Lab Sci. 2008;38:380–385.
6. Levine SJ, Stover D. Bronchoscopy and related techniques. In: Levine SJ, editor. Respiratory Disease in the Immunosuppressed Host. Philadelphia, PA: JB Lippincott; 1991:73–93.
7. Goldstein RA, Rohatgi PK, Bergofsky EH, et al. Clinical role of bronchoalveolar lavage in adults with pulmonary disease. Am Rev Respir Dis. 1990;142:481–486.
8. Clark RF, Cantrell FL, Pacal A, Chen W, Betten DP. Subcutaneous silicone injection leading to multi-system organ failure. Clin Toxicol (Phila). 2008;46:834–837.